May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Treatment of Metastatic Choroidal Breast Cancer With Bevacizumab
Author Affiliations & Notes
  • A. Varshney
    Ophthalmology Resident, Loma Linda Univ Med Center, Chino Hills, California
  • J. Carlson
    Ophthalmology Attending, Loma Linda Univ Med Center, Loma Linda, California
  • Footnotes
    Commercial Relationships  A. Varshney, None; J. Carlson, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5953. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Varshney, J. Carlson; Treatment of Metastatic Choroidal Breast Cancer With Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5953. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy of bevacizumab in the treatment of metastatic choroidal breast cancer

Methods: : A 53 year old female was diagnosed with choroidal metastasis from breast cancer in the left eye. She was started on intravenous and intravitreal bevacizumab therapy for ocular metastasis. The response of bevacizumab on ocular metastasis of breast cancer was investigated with the use of fluorescein angiography (FA), and optical coherence tomography (OCT).

Results: : Within 6 weeks of the start of intravenous and intravitreal bevacizumab therapy the patient’s best corrected visual acuity (BCVA) improved from 20/80 to 20/25. There was complete resolution of subretinal edema on optical coherence tomography with no choroidal mass evident on exam. At 10 months the patient had no subretinal fluid on OCT examination and her fluorescein angiogram showed no active leakage. There was no evidence of choroidal recurrence and her visual acuity remained 20/25.

Conclusions: : Choroidal metastasis from breast cancer appears to be very sensitive to a combination therapy of intravenous and intravitreal bevacizumab.

Keywords: tumors • choroid • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×